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The Human Papillomavirus (HPV) E4 is known to be synthesized as an E1^E4 fusion resulting from
splice donor and acceptor sites conserved across HPV types. Here we demonstrate the existence of
2 HPV-18 E2^E4 transcripts resulting from 2 splice donor sites in the 50 part of E2, while the splice
acceptor site is the one used for E1^E4. Both E2^E4 transcripts are up-regulated by keratinocyte
differentiation in vitro and can be detected in clinical samples containing low-grade HPV-18-positive
cells from Pap smears. They give rise to two fusion proteins in vitro, E2^E4-S and E2^E4-L. Whereas we
could not differentiate E2^E4-S from E1^E4 in vivo, E2^E4-L could be formally identiﬁed as a 23 kDa
protein in raft cultures in which the corresponding transcript was also found, and in a biopsy from a
patient with cervical intraepithelial neoplasia stage I-II (CINI-II) associated with HPV-18, demonstrating
the physiological relevance of E2^E4 products.
& 2012 Elsevier Inc. All rights reserved.Introduction
In the HPV compact and short (8 kb) circular genome, the
3 reading frames serve as coding sequences, with overlaps
between the different genes and extensive use of alternative
splicing. The E2 open reading frame (ORF) encodes both E2 and
E4 in different frames, a situation found to be conserved in all
sequenced HPV genomes. In HPV-16, the E4 protein has been
shown to be expressed as a fusion product between the 50 amino-
terminal residues of E1 and the full-length E4, translated from a
spliced mRNA obtained from a splice donor site in E1 and a splice
acceptor site in E2 at the beginning of the E4 ORF (Doorbar et al.,
1986, 1990). For this reason, the E4 protein is referred to as E1^E4.
With the exception of E6*^E4 mRNA, found in W12 cells expres-
sing episomal copies of the HPV-16 genome (Milligan et al., 2007),
no other fusion of HPV-16 E4 with other viral proteins has beenll rights reserved.
.sg (F. Thierry),described in the literature to day and it is therefore accepted that
the HPV-18 E4 protein is similarly exclusively expressed as an
E1^E4 fusion product. The HPV-16 E1^E4 fusion protein, which has
been better described than the HPV-18 E1^E4, is a strictly
cytoplasmic protein with multiple functions. It is expressed in
the intermediate and upper layers of the infected epithelia, and
has been shown to lead to reorganization and degradation of the
keratin intermediate-ﬁlament network, presumably to favor pro-
duction of viral particles (Doorbar et al., 1991; McIntosh et al.,
2010). It can activate apoptosis through its cytoplasmic localiza-
tion at mitochondria (Raj et al., 2004), and is able to arrest the cell
cycle in G2, presumably to create a pseudo S-phase that optimizes
conditions for viral DNA replication (Davy et al., 2002).
In addition to a role in viral DNA replication, the HPV E2 protein
has been shown to repress E6 and E7 transcription and, in HPV-18-
associated cancers, to be disrupted by integration of the viral genome
into the cellular genome (Demeret et al., 1998; Kraus et al., 2008;
Thierry and Yaniv, 1987). Recently, several unexpected functions of
the high-risk HPVs (HPV-types able to induce cancer as opposed to
low-risk types which induce only benign lesions) E2 proteins have
been described. These new functions include regulation of apoptosis
C.L. Tan et al. / Virology 429 (2012) 47–5648and cell cycle by both high-risk HPV-18 and HPV-16 E2 proteins
(Bellanger et al., 2005, 2010; Blachon et al., 2005). Also, HPV-16 E2
and E1^E4 proteins have been shown to interact with each other
leading to re-localization of E2 with E1^E4 in cytoplasmic speckles,
and their co-expression has been shown to lead to the reciprocal
stabilization of the proteins (Davy et al., 2009).
Here we show that the HPV-18 E2 gene can generate 2 differ-
ent E2^E4 proteins, one short (S) and one long (L), resulting from
alternative splicing between 1 of a possible 2 splice donor sites in
the 50 part of the E2 gene, and the classical splice acceptor site
before the E4 gene, used for E1^E4 splicing. These 2 spliced
transcripts and proteins could ﬁrst be detected in cells infected
by recombinant adenoviruses expressing HPV-18 GFP-E2 (AdGFP-
18E2), and were then found in keratinocytes transfected with the
HPV-18 genome, in which they were up-regulated by differentia-
tion. Finally, detection of the 2 transcripts in 4 independent HPV-
18-positive Pap smear clinical samples, as well as detection of the
E2^E4-L protein in HPV-18 raft cultures and a HPV-18 CIN I-II
clinical sample, provide evidence of the physiological relevance of
these new viral gene products in the HPV-18 model.Fig. 1. Two E2^E4 fusion products are generated from the E2 gene by alternative splicin
were subjected to immunoprecipitation against GFP before western-blot analyses. M
antibodies as indicated. Asterisks on each blot show the two E4-containing proteins. I¼
cells infected with AdGFP-E2 using GFPf and DBDr primers. Asterisks indicate the two
sequencing. (C) Schematic diagram showing the novel E2^E4 spliced transcripts and prot
indicate the corresponding nucleotides in the HPV-18 genome, aa¼amino acids. Sequen
antibodies showing the lack of the E2^E4-S and E2^E4-L proteins in the splice defectivResults
The HPV-18 GFP-E2-recombinant adenovirus expresses
GFP-E4-containing proteins
Through GFP-E2 Tap-Tag experiments and by mass spectro-
metry analyses, we found E4 peptides fused to GFP in AdGFP-
18E2 infected cells (data not shown). Since the cell line used was
HPV-negative, the E4 peptides must have been produced from the
E2 expression vector. Indeed, immunoprecipitation against GFP
followed by western-blots with extracts from C33 cells infected
with AdGFP-18E2, showed not only the presence of the GFP-E2
protein (shown by arrow in Fig. 1A), but also other GFP products
among which 2 proteins (around 40 and 50 kDa), also revealed
by the E4 antibody (labeled by asterisks in Fig. 1A). The lowest
band on the anti-E4 western-blot, is not present in each
experiment and is probably a degradation product of one of the
2 upper E4 products. Extract from cells infected by AdGFP was
used as a control and does not show any speciﬁc E4-containing
product.g. (A) Equal amounts of proteins from C33 cells infected with AdGFP-E2 or AdGFP
embranes were revealed with anti-GFP (left panel) or anti-18E4 (right panel)
input (1/90), B¼Beads (1/4). (B) PCR was performed on cDNAs isolated from HaCat
transcripts corresponding to the E4-containing proteins of (A) as determined by
eins. The bottom numbers indicate the nucleotides in the E2 gene, the top numbers
ces of the 2 junctions between E2 and E4 are given. (D) Western-blot using anti-E4
e mutant GFP-E2DS.
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E2 gene
We ampliﬁed the transcripts encompassing the E2 ORF pro-
duced in AdGFP-18E2 infected cells using a forward primer [GFPf]
localized at the 30 end of the GFP gene, and a reverse primer
[DBDr] at the 30 end of E2 (Fig. 1B). The major product of 1200 bp
corresponded to the full-length HPV-18 E2, while the sizes of the
2 main other products around 950 bp and 650 bp (shown by
asterisks; Fig. 1B), had compatible coding capacity for the 2 fusion
proteins described in Fig. 1A. Sequencing of these 2 cDNAs
showed that they do encode fusion proteins containing GFP
followed by 2 different amino-terminal parts of E2 (nucleotides
1–37 and 1–349) fused to the full-length E4, as depicted in Fig. 1C.
These fusion proteins are therefore translated from alternative
spliced RNAs using two splice donor sites downstream of GFP in
the 50 part of the E2 gene (nucleotides 2853 and 3165), which are
consensus sequences AAGTG and AGGTG (Fig. 5B). The 2 different
E2^E4 transcripts encode proteins of 95 (E2^E4-S, expected mole-
cular weight [MW] around 11.5 kDa) and 199 amino-acids (E2^
E4-L, 23 kDa), which are equivalent to MWs of 38.5 kDa and
50 kDa respectively when fused to GFP. We further conﬁrmed the
role of the E4 acceptor splice site by mutating it in the GFP-E2
expression vector. For this, we substituted the S residue at
position 206 to A (E2DS). As shown in Fig. 1D, the mutated
sequence prevented synthesis of the 2 GFP-E2^E4 proteins in the
transfected HeLa cells.
Design of speciﬁc primers to detect the E2^E4-S and E2^E4-L mRNAs
by Real-Time PCR
In this work we used couples of primers speciﬁc for each of the
3 spliced junctions (E1^E4, E2^E4-S and E2^E4-L). The reverse
primer targeted a downstream common sequence in E4 and the
different forward primers overlapped the sequences of the donor
and acceptor sites. Because of this overlap, the E2^E4-S and L
forward primers contained adjacent E2 and E4 sequences, and we
had to verify the speciﬁcity of their hybridization to E2^E4-S and L
compared to their hybridization to E2 and E1^E4. This was
addressed by direct Real-Time PCRs (RT-PCR) on template plas-
midic DNAs (Fig. 2A). We compared the Cts (cycle threshold)
values obtained with the 2 sets of E2^E4 primers after PCR using
their own template or E2 and E1^E4 templates. The E2^E4-S and
E2^E4-L sets of primers produced differences in ampliﬁcation
(characterized by DCts) between the non-speciﬁc and speciﬁc
templates of at least 8 (20 compared to 28) and 9 (22 compared to
31) for E2^E4-S and E2^E4-L respectively. These differences
correspond to a speciﬁcity of 99.6% for E2^E4-S primers and
99.8% for E2^E4-L primers. The level of speciﬁcity was calculated
by the formula 100[100 (1/2DCt)]. We deduced from these
calculations that the ratios E2^E4/E1^E4 and E2^E4/E2 mRNAs
must be 40.4% for E2^E4-S and 40.2% for E2^E4-L to be
signiﬁcant, and all experiments presented in this study fulﬁlled
these requirements. Sequences of primers used are given in
Materials and methods.
The E2^E4 mRNAs are detected in HPV-18-positive clinical samples
containing Pap smears cells
To look for E2^E4 transcripts in clinical samples, we ﬁrst studied
5 independent Pap smear samples collected from 5 patients,
4 presenting low grade HPV-18 lesions (patients #1, 2, 3 and 4),
and 1 presenting a low-grade HPV-58 lesion (patient #5, which we
used as a negative control). The HPV genome in infected cells from
these samples was most likely episomal since we could amplify the
E2 transcripts (Fig. 2B), which would not have been possible if theHPV genome was integrated into the E2 ORF as often occurs in
HPV-18 clinical samples (Kraus et al., 2008). However, we cannot
exclude integration in a small minority of cells. We investigated
the relative expression of the E2^E4 transcripts compared to E1^E4
and E2 in RT-PCR on total RNA using the primers described above.
All data are normalized with 18S RNA, and the graph presents
values further standardized to the E1^E4 RNA ampliﬁcation of
patient #4. The 2 E2^E4 spliced transcripts were detected in high
quantity in the 4 HPV-18-positive clinical samples when compared
to the E1^E4 transcripts, which were surprisingly low in all the
samples. However, signiﬁcant variations in transcripts levels were
seen from one sample to the next, although unspliced E2 tran-
scripts exhibited comparable levels to the spliced transcripts in
individual samples (Fig. 2B). These experiments led us to conclude
that the 2 E2^E4 spliced products are expressed in vivo and to
hypothesize that they may be actively expressed in scrapped cells
from low grade HPV-18-associated lesions due to terminal differ-
entiation of these cells.
Levels of the two E2^E4 spliced transcripts increase during
keratinocyte differentiation
To elucidate whether expression of the E2^E4 spliced tran-
scripts could be modulated by keratinocyte differentiation, we
studied their levels in an in vitro differentiating system. We used
the n-TERT keratinocyte cell line, which is immortalized by hTERT
(Dickson et al., 2000) and can differentiate in vitro if grown in RM-
medium. Differentiation was followed for 5 days by testing the
induction of involucrin and keratin 13, 2 markers of keratinocyte
terminal differentiation. After 5 days of differentiation, the global
shape of the cells changed from small cuboid cells, when not
differentiated (in KGM medium), to large strongly clustered cells
when differentiated in RM- medium (Fig. 2C, left and middle
panels). Concomitantly, levels of involucrin and keratin 13 were
elevated by the change of medium as shown by western-blot
(Fig. 2C, right panel). The total RNA from n-TERT cells transfected
by the HPV-18 genome was analyzed 5 days after induction of
differentiation, or after 5 days of culture in KGM medium as a
control (Fig. 2D, upper panel). All RT-PCR values were normalized
with 18S RNA, and the graph presents values standardized with
the value of E1^E4 transcripts ampliﬁcation in KGM set to 1
(Fig. 2D). Transcription of keratin 13 (K13) was used as a positive
control for differentiation. The levels of E2^E4-S and E2^E4-L
transcripts increased by 2.9 and 4.5-fold respectively in differ-
entiated cells, while the E1^E4 and E2 spliced mRNA were not
signiﬁcantly modulated (Fig. 2D, upper panel). Both E2^E4 alter-
natively spliced transcripts therefore appeared augmented by
keratinocyte differentiation, although their levels still remained
lower than E1^E4 levels, contrasting with Pap smear results. This
discrepancy could either be due to transcriptional activation,
stabilization of mRNA or activation of alternative splicing in cells
from Pap smears. More work is needed to elucidate as to which is
operating in this case.
The E2^E4-L protein is expressed in HPV-18 raft cultures and in a
CINI-II lesion
The HPV viral cycle can be recapitulated in vitro in 3D
keratinocyte raft cultures, which mimic epithelia structures,
allowing HPV DNA replication. We used these raft cultures to
check for the expression of the E2^E4 spliced transcripts and
proteins in more physiological conditions as compared to mono-
layer cultures. In sections of parafﬁn embedded HPV-18 rafts, we
could identify expression of E2-containing proteins by immuno-
histochemistry together with viral DNA replication by in situ
hybridization (ISH). They occur in the same upper–intermediate
Fig. 2. The 2 E2^E4 spliced mRNAs are detected in Pap smears and are enhanced by differentiation. (A) Table showing the Cts obtained for the indicated sets of primers on
the indicated plasmidic DNA. (B) Real-time PCR analyses of mRNAs extracted from 4 independent HPV-18-positive Pap smear samples using speciﬁc primers for the splice
junctions. One HPV-58-positive (instead of HPV-18) sample was used as a negative control since there is no cross hybridization of primers between HPV-18 and 58 (data
not shown). This graph represents the ratios between the values obtained for each indicated mRNA and the E1^E4 value of patient #4. All values were ﬁrst normalized to
18S rRNA. (C) Left and middle panels: phase contrast pictures showing the shapes of the n-TERT cells either not differentiated (KGM) or after 5 days of differentiation
induction (RM-). Right panel: levels of involucrin and keratin 13 in undifferentiated n-TERT cells and during the 5 days of differentiation induction. (D) Upper panel: levels
of E2^E4-S, E2^E4-L, E1^E4, E2 and keratin 13 (K13) mRNAs given by real-time PCR in undifferentiated cells (KGM) or after 5 days of differentiation (RM-). The graph
represents the ratios between the values obtained for each indicated mRNA and the E1^E4 value in KGM. Lower panel: levels of involucrin and keratin 13 in
undifferentiated cells (KGM) and after 5 days of differentiation induction (RM-) in HPV-18 transfected cells.
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protein to be localized in clinical samples containing low-grade
CIN lesions (Xue et al., 2010). Detection of E4 expression in an
adjacent section of the same raft culture showed its expression
in intermediate and upper layers, overlapping E2 expression
(Fig. 3A; right panel). However, since we could not distinguish
the spliced E2^E4 products from E2 and E1^E4 in the immunola-
beling, we performed a western-blot analysis of raft culture
extracts. The E2^E4-L protein, with an expected molecular weight
of 23 kDa, could be detected by western-blot analyses using the
HPV-18 E4 antibody as shown in Fig. 3B; left panel; raft lane.
Another more abundant E4 protein with a MW of around 10 kDa
could also be detected, which could correspond to the E1^E4 or/
and E2^E4-S products. Real-time PCR analyses of the transcripts
from an adjacent parafﬁn embedded section of the HPV-18 raft
compared to that of a normal raft, showed that the E2^E4-L
transcript was expressed (Fig. 3B; right panel), thereby validating
the western-blot data. In contrast, transcripts of the lower MWE2^E4-S isoform were below our deﬁned detection threshold.
Therefore, we deduced from these data that in HPV-18 raft
cultures, both E2^E4-L transcript and protein can be found,
although the main E4 isoform expressed is E1^E4.
We then looked at E2 and E4 expression in a HPV-18 positive
CINI-II lesion from a patient biopsy. Immunohistochemistry
staining and in situ hybridization showed that expression of E4
overlaps with E2 in the upper–intermediate layers of the lesion,
and that viral DNA replication occurs in intermediate layers
concomitantly with E2 expression, similarly to the expression
pattern in HPV-18-positive rafts (compare Fig. 3A and C). Inter-
estingly, protein extract of this sample showed expression of the
2 same proteins (23 kDa and 10 kDa) using the anti-E4 antibody
(Fig. 3B; left panel; lesion lane). This conﬁrms the presence of the
E2^E4-L product together with E1^E4 in a HPV-18-positive CIN
lesion. Attempts to analyze the transcripts were unsuccessful due
to poor quality of the RNA sample. In conclusion, data on E2^E4
expression in HPV-18 rafts and CIN conﬁrm the existence of the
Fig. 3. E2 and E4 co-localize in upper–intermediate layers of HPV-18 rafts and CIN and the E2^E4-L protein is found in extracts from the same samples. (A) Left panel: in situ
hybridization for HPV-18 DNA (dark blue staining) and E2 immunohistochemistry (brown staining) performed on HPV-18-positive raft cultures. Right panel: E4
immunohistochemistry using HPV-18 E4 antibody on an adjacent section of the same raft. (B) Left panel: western-blot analyses of proteins from adjacent sections of the
same raft (raft) and of a HPV-18 CINI-II lesion (lesion) using the HPV-18 E4 antibody; HPK: Human Primary Keratinocytes. Right panel: levels of E2^E4-L, E2 and E1^E4 given
by real-time PCR in HPV-18 raft cultures relatively to the samemRNA levels obtained from HPV-negative rafts (set to 1). (C) Upper panels: in situ hybridization performed on
the same CINI-II showing replication of viral DNA (as dark blue color of the nuclei), and immunohistochemistry showing expression of E2. Lower panels:
immunohistochemistry showing p16 expression (as a surrogate marker for E7) and immunoﬂuorescence with anti-HPV-18 E4 antibody conjugated to Alexa 488
(TVG-405). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
C.L. Tan et al. / Virology 429 (2012) 47–56 51E2^E4-L product, although the E2^E4-S protein and mRNA could
not be identiﬁed. The relative quantities of E2^E4 and E1^E4 in
rafts and CIN do not correlate with our previous observation of
relative high expression of E2^E4 compared to E1^E4 in smear
cells, but do match the in vitro results using differentiation
induction in keratinocytes. We have no explanation for this
discrepancy at present, other than a difference in the differentia-
tion status of the cells as discussed below. Detection of the E2^E4-
L protein and transcript in raft and CIN is a clear indication of a
physiological relevance of at least one of the E2^E4 isoforms
in vivo.
The two E2^E4 proteins are cytoplasmic and induce cell death
We cloned the 2 spliced cDNAs corresponding to the E2^E4-S
and E2^E4-L transcripts fused to GFP in CMV-driven expression
vectors and veriﬁed the expression and correct sizes of the
corresponding proteins by western-blot (Fig. 4A; left panel). Wethen studied the localization of each protein in transfected U2OS
cells. Fig. 4A right panel shows that the GFP-E2^E4-S protein is
expressed exclusively as cytoplasmic speckles, similar to E1^E4,
and partially co-localizes with mitochondria as shown by Mitro-
Tracker labeling (Fig. 4B). The GFP-E2^E4-L protein appears more
diffuse in the cytoplasm with some accumulation in dots (Fig. 4A;
right panel). This protein could also appear more aggregated,
depending on cell type, when highly expressed (data not shown).
Similar results were obtained with untagged E2^E4 proteins (data
not shown). Both the N-terminal domains of E2 (Thierry and
Demeret, 2008) and the E1^E4 proteins (Raj et al., 2004) have been
shown to induce apoptosis and we decided to verify whether this
was also true for the E2^E4 proteins. HeLa cells were transfected
for 30 h with expression vectors of GFP-E2, GFP-E2DS, GFP-E2^E4-
S or GFP-E2^E4-L and were subjected to propidium iodide (PI)
uptake, a method in which only the DNA of dead cells is labeled
due to membrane permeabilization. GFP-positive cells were then
selected and analyzed for PI labeling by ﬂow cytometry. As
Fig. 4. Localization and function of the E2^E4-S and E2^E4-L proteins in transfected cells. (A) Left panel: western-blot analyses showing expression and MW of the GFP-
E2^E4-S and GFP-E2^E4-L proteins in transfected HeLa cells. Asterisks indicate speciﬁc bands. Right panel: immunoﬂuorescence analyses showing localization of E1^E4 (E4
antibody directly conjugated to Alexa 488), and GFP-E2^E4-S and GFP-E2^E4-L in U2OS cells. (B) Immunoﬂuorescence analyses showing co-localization of GFP-E2^E4-S but
not GFP-E2^E4-L with mitochondria (MitoTracker staining). (C) Left panel: ﬂow cytometry analyses showing propidium iodide uptake in HeLa cells transfected with the
GFP-fused proteins as indicated. Right panel: western-blot analyses of total extracts from the same cells revealed with the anti-GFP antibody.
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(Blachon et al., 2005; Thierry and Demeret, 2008) and here we
show that the same is also true for the 2 E2^E4 proteins when
compared to GFP expression alone at comparable level (Fig. 4C, left
panel). In contrast, the E2DS mutant, which expresses only the
unspliced full-length E2 (as shown in the western-blot, Fig. 4C; right
panel), showed a reduced level of cell death, despite a higher
expression level, when compared to the wild-type expression vector
(Fig. 4C; right panel). These results indicate that apoptosis, pre-
viously solely attributed to HPV-18 E2, could in fact result from
additive activities of E2 and E2^E4 proteins when alternative splicing
is allowed. This is an important result suggesting a need to use
splice-site-defective E2 sequences to study HPV-18 E2 properties
in vitro, since E2^E4 could interfere with E2 functions.The splice donor sites in E2 are conserved in a subset of high-risk HPV
types but not in HPV-16
We then examined whether the splice donor sites in the HPV-18
E2 ORF were conserved among other HPVs by comparing the E2
sequences of various genital HPV types. None of the 2 donor sites
were found in HPV-16 due to absence of the essential dinucleotide GT
(Fig. 5B), thus corroborating previously published HPV-16 transcrip-
tion maps (Milligan et al., 2007; Sherman and Alloul, 1992; Zheng
and Baker, 2006). In agreement with absence of alternative splicing in
HPV-16 E2 expression vector, we did not detect E2^E4 proteins in
cells infected with the recombinant adenovirus expressing HPV-16
GFP-E2 (Fig. 5A). Interestingly however, the ﬁrst splice donor (SD1)
site, giving rise to the HPV-18 E2^E4-S, is conserved in 4 HPV types
Fig. 5. The splice donor sites are conserved in the E2 sequences of a subset of
high-risk HPV types but not in HPV-16. (A) Western-blot analyses of extracts from
cells infected with AdGFP-E2 from HPV-16, revealed with anti-GFP and anti-HPV-
16 E4. Transfection with an HPV-16 E1^E4 vector was used as a positive control for
detection of the HPV-16 E1^E4 protein. The 2 asterisks show the speciﬁc bands
corresponding to HPV-16 E1^E4 around 10 kDa and HPV-16 GFP-E2 around
70 kDa. (B) Sequence alignment of the splice sites in E2 proteins from the
alpha-7 group, high-risk and low-risk HPV, SD¼splice donor. The conserved
consensus sequences in E2 sequences are boxed.
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and 35, while the second splice donor site (SD2), giving rise to the
HPV-18 E2^E4-L protein, is only found in HPV-18 and HPV-97
(Fig. 5B).Discussion
We have shown here that new fusion mRNAs and proteins
between E2 and E4 (E2^E4-S and E2^E4-L) can be produced by
alternative splicing of HPV-18 E2. The 2 splice donor sites are new
sites localized at nucleotides 2853 and 3165 in the 50 part of the
E2 gene which are not described in the recently published HPV-18
transcription map (Wang et al., 2011). The acceptor site for both
spliced products was previously described for E1^E4 (nucleotide
3433). The 2 mRNAs were expressed in cells transfected with the
HPV-18 genome, as well as in 4 independent HPV-18-positive Pap
smear samples. In raft cultures, only the E2^E4-L transcript could
be unambiguously identiﬁed, and the corresponding E2^E4-L
fusion protein could be detected by western-blot. In the CINI-II
lesion, although the extracted RNA quality meant that it could notbe analyzed, the E2^E4-L protein could also be identiﬁed by
western-blotting.
Identiﬁcation of high levels of E2 expression in intermediate
layers of HPV-16 CIN lesions has recently been reported (Xue
et al., 2010), and is consistent with the localization of HPV-18 E2
obtained here in HPV-18 raft cultures as well as in the HPV-18 CIN.
In addition, our experiments unambiguously established that E2
and E4 are expressed in the same layers in low grade lesions thus
substantiating their potential functional and physical interaction as
previously reported (Davy et al., 2009). These data also indicate
that expression of the new E2^E4 proteins could take place in the
same region as E2 and E1^E4 do, and could therefore be under
similar transcriptional control in low grade lesions in vivo. It should
be noted that, although E1^E4 is clearly expressed in differentiated
cells of rafts and lesions, and although keratinocyte differentiation
induces initiation of transcription at the late promoter of HPV-16
(Grassmann et al., 1996), it is not fully demonstrated whether the
E1^E4 protein is translated from these late transcripts or from early
transcripts coming from P97 (HPV-16) and P105 (HPV-18) promo-
ters. Regarding E2, its transcription is thought to be initiated at the
early promoter, although this is not sustained by the recent
published localization of HPV-16 E2 (and the localization of HPV-
18 E2 shown here) in intermediate and upper differentiated layers
(Xue et al., 2010). In fact, E2 localization would rather be in favor of
a late transcript of E2 as suggested by Sherman and Alloul (1992).
Taking this into account, it is very difﬁcult to predict the promoter
of E2^E4. Like E2, E2^E4 mRNAs could be initiated by the early or
late promoter, although expressed in differentiated layers. In any
case, expression of E2^E4 in differentiated keratinocytes is consis-
tent with the published localization and expression of both E2 and
E1^E4 in the same layers of differentiated keratinocytes, although
regulation of their transcription is not clear. This is an important
point showing that dark zones exist in knowledge of HPV tran-
scripts, and analysis of the structure and splice regulation of viral
RNAs in vivo have to be completed to enable a greater under-
standing of the process.
In 4 independent samples from HPV-18-positive Pap smears,
the 2 spliced E2^E4 transcripts seem to be more abundant than
the E1^E4 transcript. The putative role of cell differentiation
suggested by these results was conﬁrmed in vitro in HPV-18-
transfected keratinocytes where the two E2^E4 transcripts were
up-regulated upon differentiation contrary to E1^E4. However, in
contrast to Pap smear samples where the E2^E4 transcripts prevail
over E1^E4, the levels of E2^E4 mRNAs remain lower than E1^E4 in
our in vitro system of HPV-18-differentiated monolayer keratino-
cytes and in raft cultures. At present we cannot explain this
discrepancy but hypothesize that host factors absent in in vitro
studies play a role in differentiation of keratinocytes and would
ultimately favor E2^E4 transcription or splicing compared to
E1^E4. Unfortunately, we cannot test this hypothesis due to rarity
of HPV-18-associated CIN lesions and poor quality of RNA
extracted from parafﬁn embedded tissues. Nevertheless, the E2^
E4-L protein was found in the CIN lesion analyzed indicating that
this protein is expressed under physiological conditions.
What are the expected functions of these 2 new E2^E4 fusion
proteins? The short E2^E4-S only differs from E1^E4 at its amino-
terminus, containing 12 amino-acids of E2 instead of 5 amino-
acids of E1. However, in this short E1 sequence, the second
and third amino-terminal residues, A and D, conserved between
HPV-16 and 18, have been shown to be required, together with
the LLXLL motif in E4, for association with keratins (Roberts et al.,
1994; Wang et al., 2004). The same LLXLL motif in E4 is sufﬁcient
to mediate E1^E4 mitochondrial localization (Raj et al., 2004).
Since E2^E4-S does not contain the E1 AD sequence, but contains
the E4 leucine rich motif, this new fusion protein would be
expected to display a preferential mitochondrial localization.
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les partially co-localized with MitoTracker, comparable to the
E1^E4 dots characteristic of the mitochondrial localization pre-
viously reported (Raj et al., 2004). We do not detect here the
ﬁlamentous localization of E1^E4 associated with keratins, which
might be due to lower levels of keratins in U2OS cells compared
to Cos-7 and SiHa cells used previously (Wang et al., 2004). We
show that the E2^E4-S protein is able to induce cell death in HeLa
cells as does E1^E4 (Raj et al., 2004). The similarities between
E1^E4 and E2^E4-S, the lower quantity of E1^E4 mRNA compared
to E2^E4-S detected in HPV-18 Pap smears, and the increase of the
E2^E4 alternative spliced products during keratinocyte differen-
tiation led us to hypothesize that the E2^E4-S could be an
alternative E4 product expressed by the HPV-18 genome in
productive lesions. However, this new fusion protein would not
be expected to cover all E1^E4 functions such as keratin binding
for instance, as discussed above. In contrast to the short E2^E4-S,
the long E2^E4-L protein contains a large part of the E2 protein
encompassing the 3 amino-terminal a-helices and the fulcrum
(rigid linker between the a-helices and b-sheet domains) (Antson
et al., 2000). This protein appears exclusively cytoplasmic, rather
diffuse, although it can accumulate into some dots and can
aggregate in some cell lines like HeLa when overexpressed. It
exhibits cell death-inducing properties when transfected in HeLa
cells, a characteristic also shared by E2, E1^E4 and E2^E4-S. It is
important to highlight that E2 and E1^E4 are known to interact
with each other when co-expressed, leading to delocalization of
E2 in cytoplasmic speckles where E1^E4 is primarily localized
(Davy et al., 2009). It is not surprising that E2^E4-L, which does not
contain the E2 nuclear localization domain, exhibits a different
localization to E2, which is mainly nuclear with some cytoplasmic
speckles (Blachon et al., 2005). The E2^E4-L fusion protein contains
important E2 domains involved in degradation, transactivation,
replication, apoptosis induction, and interaction with many cellular
proteins including TopBp1, Brd4, caspase 8, APC/C or SCFSkp2
(Bellanger et al., 2001, 2005, 2010; Boner et al., 2002; Thierry and
Demeret, 2008; You et al., 2004) fused to the full-length E4. This
fusion could therefore functionally correspond to a natural E2/E1^E4
heterodimer and efﬁciently mimics the interaction between the two
proteins that has been described previously (Davy et al., 2009).
The discovery of a new cytoplasmic E2^E4-L viral fusion
protein, that is restricted to a few HPV types and which is induced
by differentiation, opens up new ﬁelds for future investigations.
Indeed, we believe that it could functionally mimic the E2/E1^E4
interaction (with possibly more potent activities), but could also
exhibit new functions that might be important for the HPV-18
viral cycle as well as for HPV-18 pathophysiology.Material and methods
Cell culture, infection, electroporation and transfection
C33, HaCat, U2OS and HeLa cells were grown in Dulbecco
modiﬁed Eagle medium supplemented with 10% foetal calf serum
(FCS). n-TERT cells were grown in KGM (Keratinocyte-SFM from
Gibco, supplemented with bovine pituitary extract [25 mg/ml],
epidermal growth factor [0.2 ng/ml] and CaCl2 [0.3 mM]). These
cells were induced to differentiate in RM- (DMEM/Ham F12 v/v
[1:3], fetal calf serum [10%], L-glutamine [1%], insulin [5 mg/ml],
hydrocortisone [0.4 mg/ml], triiodothyronine [20 pM], adenine
[0.18 mM], transferrine [5 mg/mL] and CaCl2 [1.4 mM]) for 5 days
before harvesting for real-time PCR analyses.
For transfection experiments, n-TERT cells were electroporated
before differentiation with 5 mg of the HPV-18 genome DNA
(Barbosa and Schlegel, 1989) using the NEON system (Invitrogen)as per manufacturer’s instructions. HeLa cells and U2OS were
transfected with Fugene HD (Promega) or Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Infections with recombinant adenoviruses (as described in
Bellanger et al., 2001), expressing the Green Fluorescent Protein
(AdGFP) and GFP-tagged E2 (AdGFP-E2) were done at a multi-
plicity of infection (m.o.i.) of 100 (with or without 4 mg/ml of
polybrene depending on the cell line), for 1 h in DMEM without
FCS. The medium was then replaced by DMEM 10% FCS, and the
cells were harvested 24 h later for immunoprecipitation and
western-blot analyses.
Immunoprecipitation and western-blot
Cells were infected with AdGFP-18 E2 or AdGFP at m.o.i. 100
for 24 h. Proteins were extracted with an extraction buffer
(300 mM NaCl, 0.5% Nonidet P-40, 50 mM Tris-HCl [pH 8],
1 mM EDTA, protease and phosphatase inhibitors) for 30 min at
4 1C, followed by centrifugation at 13000 rpm for 30 min. Extracts
containing 1 mg of total proteins were immunoprecipitated using
GFP-Trap_A beads (ChromoTek) according to the manufacturer’s
instructions. Samples were separated by Sodium Dodecyl Sulfate-
PolyAcrylamide Gel Electrophoresis (SDS-PAGE) and analyzed by
western-blot. Proteins from the raft and CINI-II lesion were
extracted using the Qproteome FFPE Tissue Kit (Qiagen).
For western-blot experiments, anti-GFP (TP401; Torrey Pines
Biolabs) and anti-E4 polyclonal antibodies from HPV-18 (McIntosh
et al., 2010) or HPV-16 (Doorbar et al., 2000) were used.
PCR and Real-Time PCR
RNAs from HaCat cells were extracted using RNeasy mini
kit (Qiagen), treated with DNAase A and converted to cDNA using
Transcriptor First Strand cDNA synthesis kit (Roche). PCR was
performed on cDNA using GFPf (50agaagcgcgatcacatgg 30)
and DBDr (50aatggatccttacattgtcatgtatcccacc 30) primers. PCR pro-
ducts were separated on 1% agarose gel and the bands were
excised and cloned into pGEM-T easy vector (Promega). DNAs of
the positive clones were sequenced using Big Dye v3.1 (Applied
Biosystems) and analyzed using ABI-3730xl sequencer (Applied
Biosystems).
For Real-Time PCR analyses, RNAs from n-TERT and Pap
smears cells from different patients with low grade cervical
squamous intraepithelial lesions (LSIL), were extracted using
RNeasy Mini Kit (Qiagen) according to the manufacturer’s instruc-
tions. All samples were subjected to DNAse A treatment before
reverse transcription. For rafts, RNAs were extracted using RNeasy
FFPE Kit (Qiagen). Two hundred nanograms of RNA for rafts and
between 60 and 150 ng of RNA from Pap smear cells (measured
with nanodrop ND-1000) were reversed transcribed for further
analyses. For n-TERT cells, 2.5 mg of total RNA measured with
nanodrop ND-1000 were reverse-transcribed. Reverse transcrip-
tion was done using Superscript II (Invitrogen) according to the
manufacturer’s instructions. Real-time PCRs were carried out
using the Mx3005P (Stratagene) in 25 ml of mixture containing
equal amounts of cDNA, 1 mM of each primer and 12.5 ml of Sybr
Green PCR master mixture (Applied Biosystems, Asia Pte. Ltd.).
The thermal proﬁle used was 50 1C for 2 min and 95 1C for 10 min
once, then 95 1C for 15 s and 60 1C for 1 min over 40 cycles. The
dissociation curves were obtained by measuring the ﬂuorescence
from 60 1C to 95 1C. The dRn (baseline-corrected normalized
ﬂuorescence) is ﬁxed at 0.1 for all primer pairs. Importantly, to
ensure reliability of the conclusions raised, all RT-PCR results
presented here were normalized with ribosomal 18S RNA accord-
ing to Lambertini et al. (2010).
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E1^E4: GATCCAGAAATACCAGTGACG, GCCGACGTCTGGCCGTA-
GGTCTTTGCGG.
E2^E4-S: GGAACGTTTAATACCAGTGACG, GCCGACGTCTGGCCG-
TAGGTCTTTGCGG.
E2^E4-L: CTGCTTTAAAAAAGTACCAGTGA, GCCGACGTCTGGCC-
GTAGGTCTTTGCGG.
E2: CCGCTACCTGTGTAAGTCAC, CCCAAAATGTACTTCCCACG.
Immunoﬂuorescence
U2OS cells grown on cover slips were transfected with plas-
mids expressing either E1^E4, GFP-E2^E4-S or GFP-E2^E4-L for
24 h. Cover slips were rinsed with PBS and ﬁxed with PBS/2%
paraformaldehyde for 1 h in 4 1C. After rehydration, they were
permeabilized and saturated with PBS/2% serum/0.1% triton
for 30 min at 4 1C. They were then incubated with polyclonal
anti-HPV-18 E4 antibody conjugated to Alexa 488 (TVG-405, E1^E4
detection), or analyzed for direct GFP ﬂuorescence (GFP-E2^E4
detection). Nuclei were stained by 40,60-diamidino-2-phenylindole
(DAPI). Pictures were taken with Applied Precision DeltaVision
microscope system, and images were analyzed using SoftWoRx
v4.0.0.
Clinical samples
The HPV-18 lesion (CINI-II biopsy) as well as the HPV-18
smear cells from 4 different patients with low grade cervical
squamous intraepithelial lesions (LSIL) associated with HPV-18,
and 1 associated with HPV-58, were collected from NUH
(National University Hospital) in Singapore. This work has been
approved by the National University of Singapore (NUS) Institu-
tional Review Board (IRB reference code: 09-218, Approval
Certiﬁcate NUS 827). Individual participants in this study gave
written informed consent.
Raft establishment, immunohistochemistry, immunoﬂuorescence and
in situ hybridization
We used the plasmid pBS-HPV18WT as a source of HPV-18
DNA (Flores et al., 1999). Brieﬂy, the viral DNA was excised from
the pBS vector by EcoRI and the digestion products were ligated,
puriﬁed and quantiﬁed before transfection. The re-circularized
HPV-18 DNA was transfected into NIKS cells as described (Flores
et al., 2000; Lambert et al., 2005). NIKS cells (previously named
BC1-Ep/SL cells, a gift from P. Lambert) are a spontaneously
immortalized cell line that can differentiate as well as primary
keratinocytes (Allen-Hoffmann et al., 2000). Organotypic raft
cultures derived from HPV-18 harboring-NIKS cells were main-
tained on a dermal equivalent of collagen embedded with human
ﬁbroblasts (Neonatal Human Dermal Fibroblasts, CC-2509, Lonza).
Brieﬂy, the cultures were lifted to the liquid–air interface after 4
days in culture and were harvested 14 days post lift as described
(Lambert et al., 2005). The rafts were ﬁxed in 4% formalin,
embedded in parafﬁn, and cut into 5-mm-thick serial sections.
Immunohistochemistry was performed on serial sections of
parafﬁn-embedded rafts or lesions using the Vectastain ABC kit
rabbit (Vectastain ABC Kit Rabbit IgG PK-4001, Vector Labora-
tories). The slides were dewaxed in xylene and rehydrated in a
graded series of alcohol washes. After dewaxing, epitope retrieval
was performed by heating the sections at 96 1C for 40 min in
10 mM citrate buffer (pH 6.0). After washing in tap water,
endogenous peroxidase activity was blocked by incubation in
0.3% hydrogen peroxide for 30 min, and then blocked by incuba-
tion in PBS 2% BSA 2% normal goat serum, for 60 min. For
immunohistochemistry, primary antibodies (anti-HPV-18 E4,
anti-E2 antibodies (Xue et al., 2010), anti-p16 [clone JC8, SantaCruz]) were added for 1 h at room temperature and detected
using the Vectastain ABC kit as speciﬁed by the manufacturer.
AEC substrate was added for color revelation. Slides were coun-
terstained with hematoxylin and mounted with Aquatex. For
immunoﬂuorescence, anti-HPV-18 E4 antibody conjugated to
Alexa 488 (TVG-405) was added together with DAPI for 1 h. The
in situ hybridization was performed with the wide spectrum HPV
biotinylated DNA probe sets able to detect 11 types of anogenital
HPV (In Situ Hybridization System [K0601], Dako) according to
manufacturer’s instructions.
Propidium iodide uptake
HeLa cells were harvested and immediately labeled with 1 mg/ml
propidium iodide (PI) without ﬁxation. They were then subjected to
ﬂow cytometry analyses using the LSRII ﬂow cytometer (BD
Biosciences). Analyses were performed with the WinMDI software.Fundings
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